Kailera Therapeutics (NASDAQ:KLRA) Stock Price Crosses Below Fifty Day Moving Average – Should You Sell?

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA – Get Free Report) crossed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $12.40 and traded as low as $11.86. Kailera Therapeutics shares last traded at $12.20, with a volume of 510,056 shares traded.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on KLRA shares. Weiss Ratings upgraded shares of Kailera Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Wednesday, October 21st. Canaccord Genuity Group began coverage on shares of Kailera Therapeutics in a research note on Monday, November 9th. They set a “buy” rating and a $44.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Kailera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.00.

Check Out Our Latest Stock Analysis on KLRA

Kailera Therapeutics Trading Down 2.9%

The firm has a 50-day moving average price of $12.40 and a 200-day moving average price of $17.47. The company has a market capitalization of $1.58 billion and a price-to-earnings ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.81. Equities research analysts predict that Kailera Therapeutics, Inc. will post -3.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Commonwealth Equity Services LLC acquired a new stake in shares of Kailera Therapeutics during the third quarter valued at approximately $134,000. Tidal Investments LLC acquired a new position in Kailera Therapeutics in the 2nd quarter worth approximately $309,000. Profund Advisors LLC acquired a new position in Kailera Therapeutics in the 3rd quarter worth approximately $216,000. Cibc World Market Inc. grew its position in Kailera Therapeutics by 4.8% during the 3rd quarter. Cibc World Market Inc. now owns 37,181 shares of the company’s stock worth $425,000 after purchasing an additional 1,705 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in Kailera Therapeutics during the 2nd quarter worth approximately $993,000.

Kailera Therapeutics Company Profile

(Get Free Report)

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing medicines for obesity and related metabolic diseases. Its research focuses on treatments that act on biological pathways involved in appetite, weight regulation and metabolism. The company’s pipeline includes investigational injectable and oral therapies, including programs designed to target GLP-1 and GIP receptors. These products are in development and are not approved for commercial use. Founded in 2024, Kailera has secured development and commercialization rights outside Greater China to drug candidates discovered by Jiangsu Hengrui Pharmaceuticals.

Recommended Stories

Receive News & Ratings for Kailera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kailera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.